Intrexon | XON - صافي الدخل





صافي الدخل تغيير تاريخ
Agenus USD -10.63M 74.49M 2025-12
Alaunos Therapeutics USD -1.16M 108K 2025-09
Amgen USD 1.82B 486M 2026-03
Anika Therapeutics USD 292K 2.62M 2025-12
Arrowhead Research USD 30.81M 54.56M 2025-12
AstraZeneca USD 3.08B 754M 2026-03
Bristol-Myers Squibb USD 2.68B 1.59B 2026-03
Gilead Sciences USD 2.18B 869M 2025-12
GlaxoSmithKline GBP 1.74B 1.1B 2026-03
Heron Therapeutics USD -2.95M 14.54M 2025-12
Incyte USD 303.33M 4.05M 2026-03
Karyopharm Therapeutics USD -102.2M 71.42M 2025-12
Ligand Pharmaceuticals USD 117.27M 112.43M 2025-09
MacroGenics USD -14.16M 30.98M 2025-12
MannKind USD -15.95M 23.93M 2025-12
Merck USD -4.24B 7.2B 2026-03
Novartis USD 3.16B 747M 2026-03
Rigel Pharmaceuticals USD 12.42M 13.45M 2024-09
Roche Holding CHF 5.47B 1.76B 2025-12
Sangamo BioSciences USD -36.13M 12.96M 2024-06
Thermo Fisher Scientific USD 1.65B 313M 2026-03
Veracyte USD 41.15M 22.01M 2025-12
Xencor USD -6.65M 626K 2025-12